|
1. Biologie
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.4 Traitements - Economie
|
|
|
Is ASCO Sending Mixed Messages On Cancer Drug Value? [Forbes]
|
|
|
|
|
|
Integrating
input from multiple stakeholders may help improve usability of ASCO's
value framework. As currently constituted, ASCO scores are unable to
readily differentiate between drugs providing more or less value,
because costs and benefits cannot be combined into one measure.
|
|
|
|
|
|
|
|
5.9.3 EHA
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
Vitamin D Levels Linked to Lower Colorectal Cancer Risk [ACS]
|
|
|
|
|
|
According
to Marjorie L. McCullough, ScD, RD, American Cancer Society
epidemiologist and co-first author of the study, the findings indicate
there may be a target range of vitamin D levels that may optimally lower
risk for colorectal cancer. She said, “What’s optimal for colorectal
cancer may be different for what’s optimal for bone health.”
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|